文献速递肥胖与代谢综合征性腺与生殖内分泌

肥胖与乳腺癌风险:代谢失调的致癌意义

Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本文综述肥胖与乳腺癌风险的关联,检索PubMed相关文献。高体重指数和体重增加与绝经后激素受体阳性乳腺癌风险升高相关,体成分不良指标在任意体重者中也可能增加风险。减重及脂肪量减少可改善代谢、炎症标志物、性激素水平和乳腺密度,提示与乳腺癌风险降低有关。

要点

  • 高体重指数和体重增加与绝经后激素受体阳性乳腺癌风险升高相关。
  • 任意体重者的体成分不良指标也可能与乳腺癌风险升高相关。
  • 减重及脂肪量减少可改善代谢、炎症标志物、性激素水平和乳腺密度。

核心结论

  • 将代谢健康标志物和体成分指标与体重指数结合可更全面捕捉乳腺癌风险。
  • 需要进一步研究针对体脂水平的干预措施以遏制肥胖相关癌症患病率增长。

研究设计与样本

  • PubMed文献检索,使用「肥胖」「乳腺癌风险」「饮食」「运动」「体重增加」「体重减轻」「脂肪组织炎症」「皇冠状结构」「免疫标志物」「二甲双胍」「gliflozins」「SGLT-2i」「GLP1-RA」及相关术语的组合。

主要发现

  • 高体重指数和体重增加与绝经后激素受体阳性乳腺癌风险升高相关。
  • 新出现的证据提示任意体重者的体成分不良指标也可增加乳腺癌风险。
  • 脂肪因子平衡改变、脂肪组织功能障碍、胰岛素信号失调和慢性炎症等多种因素参与肿瘤发生。
  • 通过生活方式和药物干预实现的体重减轻及更具体的脂肪量减少可改善血清代谢和炎症标志物、性激素水平及乳腺密度,提示与乳腺癌风险降低相关。

临床怎么用

  • 将代谢健康标志物和体成分指标与体重指数结合可更全面捕捉乳腺癌风险。
  • 需要进一步研究针对体脂水平的干预措施以遏制肥胖相关癌症患病率增长。

局限性

  • 需要进一步研究针对体脂水平的干预措施以遏制肥胖相关癌症患病率增长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Breast cancer is increasing in prevalence in parallel with rising rates of obesity worldwide. Obesity is recognized as a leading modifiable risk factor for the development of breast cancer; however, this association varies considerably by clinicopathologic features, and the underlying mechanisms are complex. EVIDENCE ACQUISITION: Pubmed literature search using combinations of "obesity," "breast cancer risk," "diet," "exercise," "weight gain," "weight loss," "adipose tissue inflammation," "crown-like structure," "immune markers," "metformin," "gliflozins," "SGLT-2i," "GLP1-RA," and related terms. EVIDENCE SYNTHESIS: Elevated body mass index and weight gain are associated with increased risk of postmenopausal, hormone receptor-positive breast cancer. Emerging evidence suggests that adverse measures of body composition in individuals of any weight can also confer increased breast cancer risk. Mechanistically, various factors including altered adipokine balance, dysfunctional adipose tissue, dysregulated insulin signaling, and chronic inflammation contribute to tumorigenesis. Weight loss and more specifically fat mass loss through lifestyle and pharmacologic interventions improve serum metabolic and inflammatory markers, sex hormone levels, and measures of breast density, suggesting a link to decreased breast cancer risk. CONCLUSION: Incorporating markers of metabolic health and body composition measures with body mass index can capture breast cancer risk more comprehensively. Further studies of interventions targeting body fat levels are needed to curb the growing prevalence of obesity-related cancer.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Naaman SC, Shen S, Zeytinoglu M, et al. Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation. J Clin Endocrinol Metab. 2022. PMID: 35453151. doi:10.1210/clinem/dgac241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。